Literature DB >> 22137879

Effects of a nationwide Hib vaccine shortage on vaccination coverage in the United States.

Tammy A Santibanez1, Abigail Shefer, Elizabeth C Briere, Amanda C Cohn, Amy V Groom.   

Abstract

BACKGROUND: A shortage of Haemophilus influenzae type b (Hib) vaccine that occurred in the United States during December 2007 to September 2009 resulted in an interim recommendation to defer the booster dose, but to continue to vaccinate as recommended with the primary series during the first year of life.
OBJECTIVES: To quantify effects of the Hib shortage on vaccination coverage and to determine if any demographic subgroups were disproportionately affected.
METHODS: Data from the 2009 National Immunization Survey (NIS) were divided based on child's age at the onset of the shortage. Comparisons were made in primary series coverage by 9 months between children <7 months versus ≥7 months at the start of the shortage. Comparisons in primary series plus booster dose completion by 19 months were made between children who were <12 months versus ≥12 months at the start of the shortage.
RESULTS: Nationally, there was a difference in Hib primary series completion by 9 months among children age <7 months versus ≥7 months at the start of the shortage (73.9% versus 81.2%, P<0.001). There was a large difference in the percentage of children fully vaccinated with the primary series plus booster dose by 19 months among children age <12 months versus ≥12 months at the start of the shortage (39.5% versus 66.0%, P<0.001). There were differential effects of the shortage on primary series coverage among states and for some demographic characteristics.
CONCLUSIONS: As expected booster dose coverage was reduced consistent with interim recommendations, but primary series coverage was also reduced by 7 percentage points nationally. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22137879     DOI: 10.1016/j.vaccine.2011.11.075

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Lessons Learned From Making and Implementing Vaccine Recommendations in the U.S.

Authors:  L Reed Walton; Walter A Orenstein; Larry K Pickering
Journal:  Am J Prev Med       Date:  2015-08-18       Impact factor: 5.043

2.  Bacterial exploitation of phosphorylcholine mimicry suppresses inflammation to promote airway infection.

Authors:  Christopher B Hergott; Aoife M Roche; Nikhil A Naidu; Clementina Mesaros; Ian A Blair; Jeffrey N Weiser
Journal:  J Clin Invest       Date:  2015-08-31       Impact factor: 14.808

3.  Haemophilus influenzae type b disease and vaccine booster dose deferral, United States, 1998-2009.

Authors:  Elizabeth C Briere; Michael Jackson; Shetul G Shah; Amanda C Cohn; Raydel D Anderson; Jessica R MacNeil; Fatima M Coronado; Leonard W Mayer; Thomas A Clark; Nancy E Messonnier
Journal:  Pediatrics       Date:  2012-08-06       Impact factor: 7.124

4.  Factors associated with the pricing of childhood vaccines in the U.S. public sector.

Authors:  Weiwei Chen; Mark Messonnier; Fangjun Zhou
Journal:  Health Econ       Date:  2017-06-29       Impact factor: 3.046

Review 5.  Assessing the Importance of Domestic Vaccine Manufacturing Centers: An Overview of Immunization Programs, Vaccine Manufacture, and Distribution.

Authors:  Emma Rey-Jurado; Felipe Tapia; Natalia Muñoz-Durango; Margarita K Lay; Leandro J Carreño; Claudia A Riedel; Susan M Bueno; Yvonne Genzel; Alexis M Kalergis
Journal:  Front Immunol       Date:  2018-01-18       Impact factor: 7.561

6.  State-level trends in sudden unexpected infant death and immunization in the United States: an ecological study.

Authors:  Jacqueline Müller-Nordhorn; Konrad Neumann; Thomas Keil; Stefan N Willich; Sylvia Binting
Journal:  BMC Pediatr       Date:  2021-06-11       Impact factor: 2.125

7.  Are we speaking the same language? an argument for the consistent use of terminology and definitions for childhood vaccination indicators.

Authors:  Shannon E MacDonald; Margaret L Russell; Xianfang C Liu; Kimberley A Simmonds; Diane L Lorenzetti; Heather Sharpe; Jill Svenson; Lawrence W Svenson
Journal:  Hum Vaccin Immunother       Date:  2018-12-20       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.